NYSE: ZBHZimmer Biomet

    Zimmer Biomet Q3 2026 Results: Net Income $192 Million on Revenue of $2.06 Billion

    • US stocks
    • Earnings
    • Health Care
    Assorted tablets and capsules in white, pink, yellow, blue and orange
    freestocks.org freestocks, via Wikimedia Commons (CC0). Illustrative image.

    Zimmer Biomet (NYSE: ZBH) reported GAAP revenue of $2.06 billion and GAAP net income of $191.6 million for the third quarter of 2026, the quarter ended 30 Sep 2026, and it said on 4 Nov 2026. GAAP diluted EPS was $1.00, and adjusted diluted EPS, a company-defined measure, was $1.90.

    Key highlights

    • Revenue (GAAP): $2.06 billion, up 3.1% YoY and down 5.2% QoQ
    • Net income (GAAP): $191.6 million, down 17.0% YoY
    • Diluted EPS (GAAP): $1.00, down 13.8% YoY
    • Adjusted diluted EPS (company-defined): $1.90, the same as a year earlier
    • Free cash flow (company-defined): $372.4 million

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue2,062.92,001.4+3.1%2,177.0-5.2%
    307.6351.3-12.4%326.1-5.7%
    191.6230.9-17.0%198.3-3.4%
    Diluted EPS ($)1.001.16-13.8%1.03-2.9%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    Against a year earlier, GAAP revenue rose 3.1% to $2.06 billion from $2.00 billion, while operating income fell 12.4% to $307.6 million from $351.3 million. Operating income was 14.9% of revenue, against 17.6% a year earlier. Against the previous quarter, revenue fell 5.2% and diluted EPS fell 2.9% from $1.03.

    Adjusted figures exclude amortization and specific charges

    The company's adjusted figures are company-defined measures that exclude items it names, including intangible asset amortization of $166.0 million, restructuring charges of $14.4 million and acquisition-related charges of $19.6 million. On that basis, adjusted net earnings were $362.8 million and adjusted operating profit was $518.8 million, an adjusted operating profit margin of 25.1%.

    Knees declined while Hips and S.E.T. grew

    Net sales rose 3.7% on a constant currency basis, a company-defined measure. Knees net sales were $767.5 million, down 3.1%, while Hips rose 6.0% to $536.5 million, S.E.T. rose 6.8% to $578.3 million, and Technology & Data, Bone Cement and Surgical rose 11.9% to $180.6 million.

    Full-year 2026 guidance was updated

    The company now expects reported revenue change of 4.4% to 4.9% for 2026, against 3.9% to 4.9% before, and organic constant currency revenue change of 3.0% to 3.5%, against 2.25% to 3.25%. It also expects adjusted diluted EPS of $8.50 to $8.60, against $8.47 to $8.59 before.

    Inference

    Diluted weighted average shares were 191.4 million in the quarter, against 198.8 million a year earlier. Over the nine months to 30 Sep 2026 the company repurchased $579.3 million of its common stock, against $237.0 million a year earlier, and paid $139.2 million in dividends to stockholders.

    The release does not give a GAAP reconciliation of the 2026 adjusted diluted EPS guidance, which the company says is not available without unreasonable efforts, or the expected cost of the September 2026 restructuring programs. The next dated point it gives is the full-year 2026 outlook, which ends 31 Dec 2026.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts